Recall Due to Botulism Outbreak in 12 States

Black keyboard with Product Recall yellow key.

Families across America are facing new fears as a botulism outbreak tied to infant formula exposes alarming regulatory gaps and market vulnerabilities.

Story Snapshot

ByHeart infant formula recalled nationwide after botulism outbreak hospitalized 15 infants in 12 states.
ByHeart accounts for only 1% of U.S. formula sales but is linked to over 40% of formula-exposed cases.
First confirmed U.S. outbreak of infant botulism linked to powdered formula; all affected infants hospitalized, no deaths.
FDA, CDC, and state agencies expand investigation as parents demand greater oversight and safety reforms.

ByHeart Formula Recall Sparks Nationwide Concern

On November 8, 2025, ByHeart recalled all unexpired lots of its Whole Nutrition Infant Formula after public health officials confirmed a multistate outbreak of infant botulism. The recall followed weeks of rising cases, with at least 15 infants hospitalized across 12 states. Epidemiological investigations and laboratory testing implicated ByHeart formula as the source. California health authorities found Clostridium botulinum in an open can fed to an affected infant, prompting urgent regulatory action and widespread parental alarm.

ByHeart’s market share stands at only around 1% nationally, yet the brand is linked to over 40% of formula-exposed cases in this outbreak. This disproportionate representation has intensified scrutiny from federal regulators and sparked concerns about manufacturing practices. ByHeart, known for its organic products, voluntarily recalled its formula, stating that no contamination had been confirmed in unopened cans but that the risk warranted immediate action to protect infant health.

Regulatory Response and Industry Implications

Federal agencies including the FDA and CDC have expanded their investigation, urging parents to discontinue use of ByHeart formula and dispose of any remaining product. No deaths have been reported, but the hospitalization of all affected infants underscores the severity of the outbreak. The recall and investigation come amid heightened concern about infant formula safety, following earlier recalls and shortages that left families vulnerable. The current crisis has reignited calls for stricter oversight, transparency, and accountability from manufacturers and regulators alike.

Industry experts note that infant botulism is rare and typically linked to environmental exposure or honey, not formula. This outbreak marks the first confirmed U.S. instance of infant botulism tied to powdered formula, raising questions about existing safety protocols. Experts emphasize the need for more robust manufacturing controls, rigorous testing, and clear communication with consumers. Families affected by the recall face immediate disruption, while broader trust in formula products has been shaken.

Impact on Families and Policy Reform

For affected families, the outbreak has brought anxiety and urgent medical needs. Hospitalization and treatment for infants have placed emotional and financial strain on parents, many of whom relied on ByHeart for perceived nutritional quality. The recall’s ripple effects extend to retailers, distributors, and healthcare providers, all facing heightened scrutiny. The FDA and CDC continue to monitor cases, with laboratory results from ongoing tests expected in the coming weeks.

Infant Formula Company Tied to Botulism Outbreak Had Known Problems
A Pennsylvania plant run by the company, ByHeart, was shut down this year after inspectors found mold, a leaking roof and more than 2,500 dead insects in a food production areahttps://t.co/BSsXClmYCL

— Christi Givens (@ChristiGivens3) November 14, 2025

Long-term consequences for ByHeart may include lasting reputational damage and potential legal liabilities. Across the industry, manufacturers are likely to face more stringent safety requirements, while policymakers weigh reforms to prevent future outbreaks. The event highlights the vulnerabilities in the infant nutrition sector and the need for vigilant regulatory action to safeguard the health of America’s youngest citizens.